$459.80
Manufacturer: Italy
Treatment of infections in adults and children older than 1 year caused by microorganisms sensitive to the drug: intra-abdominal infections; lower respiratory tract infections (severe pneumonia, including hospital and ventilator-associated pneumonia) Intranatal and postpartum infections; infections of the genitourinary system; skin and soft tissue infections; bone and joint infections; septicaemia, endocarditis. The drug can be used in the treatment of patients with neutropenia, accompanied by fever, the likely cause of which is a bacterial infection. Treatment of patients with bacteremia that is associated or likely associated with any of the above infections.
Description
Imipenem/Cilastatin Composition
active ingredients: imipenem; cilastatin.
1 bottle contains imipenem (as imipenem monohydrate) 500 mg and cilastatin (as cilastatin sodium) 500 mg;
Excipient:
sodium bicarbonate.
Imipenem/Cilastatin Dosage form.
Powder for solution for infusion.
Basic physical and chemical properties: powder from white to almost white or slightly yellowish.
Pharmacotherapeutic group. Antibacterial agents for systemic use, Carbapenems. Imipenem and an enzyme inhibitor.
ATX code J01D H51.
Imipenem/Cilastatin Pharmacological properties
Pharmacodynamics.
Zilpen consists of two components: imipenem, the first representative of a new class of β-lactam antibiotics – thienamycins, and cilastatin sodium, a special inhibitor of an enzyme that blocks the metabolism of imipenem in the kidneys and significantly increases the concentration of unchanged imipenem in the urinary tract. The weight ratio of imipenem and cilastatin sodium in the preparation is 1: 1.
The class of thienamycin antibiotics, to which imipenem belongs, is characterized by a wider spectrum of potent bactericidal action than that provided by any of the studied antibiotics.
Zilpen is indicated for the treatment of mixed infections caused by strains of aerobic and anaerobic bacteria susceptible to it. Cilpen has been shown to be effective in the treatment of many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandoluftazimu. A large number of infections caused by aminoglycoside-resistant (gentamicin, amikacin, tobramycin) and / or penicillins (ampicillin, carbenicillin, penicillin-G, ticarcillin, piperacillin, azlocillin, mezlocillin) pathogens can also be treated with this combination.
Indications
Treatment of infections in adults and children aged 1 year and older caused by microorganisms sensitive to the drug:
intra-abdominal infections;
lower respiratory tract infections (severe pneumonia, including hospital and ventilator-associated pneumonia);
intrapartum and postpartum infections;
complicated infections of the genitourinary system;
complicated infections of the skin and soft tissues;
infections of bones and joints;
septicemia;
endocarditis.
The drug can be used in the treatment of patients with neutropenia, accompanied by fever, the likely cause of which is a bacterial infection.
Treatment of patients with bacteremia associated or likely associated with any of the above infections.
Contraindications
Hypersensitivity to any of the components of the drug, other drugs of carbapenem, acute manifestations of hypersensitivity (for example, anaphylactic reactions, severe skin reactions) to other ß-lactam antibiotics (for example, to penicillin or cephalosporins).
Recent Reviews